CNS Drugs. 1997 Apr;7(4):328-40. doi: 10.2165/00023210-199707040-00005.

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs

A Markham, P Benfield

PMID: 27520755 DOI: 10.2165/00023210-199707040-00005

Abstract

SYNOPSIS: The semisynthetic ergotine dopamine agonist pergolide has demonstrated activity at pre- and postsynaptic dopamine D2 receptors in vitro and in vivo animal studies. However, unlike other dopamine agonists such as bromocriptine, pergolide also has agonist activity at dopamine D1 receptors. Certain other pharmacological effects of pergolide, such as reduction of dopamine turnover and effects on free radical scavenging enzymes, may be relevant in the early treatment of Parkinson's disease but this has not been conclusively determined. Short and long term noncomparative studies show that pergolide is an effective adjunct to levodopa therapy in patients with advancing Parkinson's disease, reducing the adverse effects of long term levodopa monotherapy and often enabling a reduction in levodopa dosage. In placebo comparisons pergolide was generally more effective than placebo and was associated with benefits similar to those seen in noncomparative studies. Longitudinal comparisons in individual patients indicate that the antiparkinsonian efficacy of pergolide is similar to that of mesulergine, lergotrile and lisuride, and may be superior to that of bromocriptine. Controlled comparisons with bromocriptine tend to support this latter finding. Studies evaluating the efficacy of pergolide as monotherapy early in the course of Parkinson's disease have shown the drug to be effective, but opinion is divided as to the value of early treatment with dopamine agonists (as opposed to levodopa monotherapy). Thus, pergolide is an effective adjunct to levodopa therapy in patients with advanced Parkinson's disease and may have a role in the treatment of early disease if its postulated beneficial effects on disease progression are proven.

PHARMACODYNAMIC PROPERTIES: Pergolide is a semisynthetic ergoline dopamine agonist used in the treatment of Parkinson's disease. It has potent activity at presynaptic dopamine D2 receptors but is also active at postsynaptic D2 and dopamine D1 receptors. In vitro, pergolide suppressed D2-mediated prolactin release from rat anterior pituitary fragments and inhibited potassium-mediated dopamine or acetylcholine release from rat caudate slices. Pergolide-induced activation of rat striatal D1 receptors has been shown to stimulate adenylate cyclase activity which, in turn, increased production of cyclic AMP. The majority of receptor binding studies indicate that pergolide is considerably more selective for D2 than for D1 receptors. In vivo, pergolide has been shown to induce contralateral turning in rats with right-side nigrostriatal lesions; it also induced climbing in rats selected on the basis of a climbing response to apomorphine. Pergolide had similar actions to those of selective D2 agonists in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys but was more potent than selective D1 agonists. Pergolide improved parkinsonian symptoms in another study in this model. Its effects were more marked, but of shorter duration, than those of bromocriptine or cabergoline. One theory regarding the cause of Parkinson's disease is that metabolism of dopamine produces free radicals which damage nigral neurons. Its effects on oxygen radical scavenging enzymes are unclear; the drug induced Superoxide dismutase in one in vivo animal study but had no effect in another (but did induce catalase and glutathione peroxidase).

PHARMACOKINETIC PROPERTIES: Single 1, 2, 5 and 10mg doses of pergolide produced mean peak plasma concentrations (Cmax) of 2.09, 4.57, 20.3 and 26 μg/L, respectively, in rhesus monkeys (administration of therapeutic doses to volunteers was considered unethical). The time to Cmax ranged between 2.4 and 2.7 hours at all dose levels. Mean steady-state pergolide plasma concentrations of 0.0275 to 1.167 μg/L were recorded during treatment with pergolide 2.25 to 9 mg/day in patients with Parkinson's disease; extensive interpatient variability was noted. 55% of a 0.138mg radiolabelled oral dose of pergolide was excreted in the urine of volunteers; a further 40 to 50% of radioactivity appeared in the faeces and approximately 3% appeared in expired air. Analysis of urine and faecal extracts indicated the formation of 10 or more metabolites.

THERAPEUTIC USE: A large noncomparative Japanese study has evaluated the short term efficacy of pergolide in combination with levodopa ± carbidopa (n = 314) or as monotherapy (n = 86). Addition of pergolide allowed a significant reduction in levodopa dosage and about 65% of patients experienced at least a mild improvement in wearing off and on-off phenomena. 45.3% of monotherapy recipients experienced at least moderate improvement according to a final global rating scale (vs 52.9% of combination therapy recipients). Additional noncomparative studies in Australian, Thai, Chinese and Italian patients also reported adjunctive pergolide therapy to be effective. Early noncomparative long term studies reported an initial response to pergolide but the rate of clinical improvement tended to peak after 2 to 12 months, then decline. However, it does appear that the efficacy of pergolide, despite waning, can be maintained at a satisfactory level for several years. A long term continuation of the Japanese study discussed above reported a final global improvement rate that was at least moderate in 51.4% of adjunctive pergolide therapy recipients treated for at least 1 year, although the drug tended to become less effective after this time. 62 monotherapy recipients were included in this long term continuation; final global improvement rates were similar (moderate or greater in 61.3% of monotherapy recipients vs 51.4% in the combination therapy group). Results from a large 6-month multicentre double-blind placebo comparison have confirmed the result of earlier, smaller placebo comparisons. Pergolide recipients (n = 189) experienced a significantly greater improvement in many subjective measures of disease severity than placebo recipients. Pergolide allowed a 24.7% reduction in levodopa dosage compared with an approximate 5% reduction with placebo. On the basis of longitudinal sequential comparisons in individual patients, pergolide was considered to have similar utility to mesulergine, lergotrile and lisuride and appeared to be more effective than bromocriptine. In addition, a number of controlled studies reported that although both drugs were useful, pergolide tended to allow a greater reduction in levodopa dosage than bromocriptine. The sole available comparison of pergolide and bromocriptine as monotherapy reported the 2 drugs to be similarly effective.

TOLERABILITY: Postural hypotension occurs quite frequently in patients starting pergolide therapy but usually diminishes over time. In a recent placebo comparison, adverse events occurring significantly more frequently in pergolide recipients included dyskinesia (62% in the pergolide group vs 25% in placebo recipients), nausea (24 vs 13%), hallucinations (14 vs 3%), drowsiness (10 vs 3%), insomnia (8 vs 3%), nasal congestion (7 vs 1%), dyspepsia (6 vs 2%) and dyspnoea (5 vs 1%). ECG changes and palpitations have been noted in some patients receiving pergolide during clinical trials and close observation may be needed in patients with concomitant heart disease; limited data indicate that addition of domperidone attenuates these cardiac adverse events. Rarely, abrupt withdrawal of pergolide therapy can cause confusion or hallucinations; thus, when required, cessation of pergolide therapy should be gradual.

DOSAGE AND ADMINISTRATION: To avoid first dose hypotension and other adverse effects such as nausea and vomiting, pergolide therapy must be initiated at a low dosage (often 0.05 mg/day for 2 days). The dose should be slowly increased until maximum clinical benefit is achieved with no or minimal adverse effects. The drug is administered in divided doses, usually 3 or 4 times per day, and the most frequent effective total daily dose is 3 to 4mg; however, mean effective dosages were somewhat lower in Japanese studies.

References

1. Psychopharmacology (Berl). 1990;100(1):19-26 - PubMed
2. Neurology. 1985 Mar;35(3):296-9 - PubMed
3. Can J Neurol Sci. 1987 Aug;14(3 Suppl):466-73 - PubMed
4. Neurology. 1985 May;35(5):738-42 - PubMed
5. Neurobiol Aging. 1992 Mar-Apr;13(2):339-51 - PubMed
6. Ann Neurol. 1982 Sep;12(3):243-7 - PubMed
7. Neurol Clin. 1992 May;10(2):527-40 - PubMed
8. J Neurol. 1984;231(3):148-52 - PubMed
9. Eur Neurol. 1986;25(2):86-90 - PubMed
10. Clin Chem. 1992 Oct;38(10):1975-80 - PubMed
11. J Neural Transm Park Dis Dement Sect. 1995;10(1):55-62 - PubMed
12. CNS Drugs. 1996 May;5(5):369-88 - PubMed
13. Adv Neurol. 1983;37:95-108 - PubMed
14. Neurology. 1983 Aug;33(8):1009-14 - PubMed
15. Clin Neuropharmacol. 1985;8(3):260-5 - PubMed
16. J Pharmacol Exp Ther. 1993 Jun;265(3):1387-91 - PubMed
17. Neurology. 1985 Mar;35(3):291-5 - PubMed
18. Eur J Pharmacol. 1983 Feb 18;87(2-3):183-9 - PubMed
19. Mayo Clin Proc. 1988 Oct;63(10):979-87 - PubMed
20. J Clin Neurosci. 1996 Jul;3(3):234-8 - PubMed
21. Neurology. 1984 Jul;34(7):983-6 - PubMed
22. Clin Ter. 1991 Jan 15;136(1):39-45 - PubMed
23. Drugs. 1993 Sep;46(3):384-393 - PubMed
24. Arzneimittelforschung. 1993 Apr;43(4):409-12 - PubMed
25. Neurology. 1989 Aug;39(8):1121-2 - PubMed
26. Clin Neuropharmacol. 1987 Apr;10(2):178-85 - PubMed
27. Neurology. 1993 Nov;43(11):2170-2 - PubMed
28. Neurology. 1982 Oct;32(10):1181-4 - PubMed
29. Annu Rev Neurosci. 1993;16:299-321 - PubMed
30. Adv Neurol. 1984;40:537-9 - PubMed
31. Mov Disord. 1994 Jan;9(1):40-7 - PubMed
32. Neurosci Lett. 1993 Dec 24;164(1-2):41-3 - PubMed
33. Clin Pharmacol Ther. 1981 Aug;30(2):258-65 - PubMed
34. J Med Assoc Thai. 1996 Apr;79(4):205-9 - PubMed
35. J Pharmacol Exp Ther. 1989 Jul;250(1):227-35 - PubMed
36. Neurology. 1985 May;35(5):749-51 - PubMed
37. Neurology. 1995 Mar;45(3 Suppl 3):S22-7 - PubMed
38. Clin Neuropharmacol. 1986;9(2):160-4 - PubMed
39. Neurology. 1981 Jun;31(6):675-82 - PubMed
40. Arzneimittelforschung. 1993 Mar;43(3):281-6 - PubMed
41. Adv Neurol. 1984;40:509-13 - PubMed
42. Adv Neurol. 1983;37:75-83 - PubMed
43. Life Sci. 1991;49(13):925-30 - PubMed
44. Drugs. 1990 Mar;39(3):491-506 - PubMed
45. Br J Pharmacol. 1991 Jan;102(1):45-50 - PubMed
46. Arch Neurol. 1983 Dec;40(13):785-7 - PubMed
47. Zhonghua Yi Xue Za Zhi (Taipei). 1995 Nov;56(5):312-8 - PubMed
48. Neurology. 1984 Feb;34(2):223-6 - PubMed
49. Am J Med Sci. 1991 Apr;301(4):277-80 - PubMed
50. Am J Med Sci. 1985 Sep;290(3):102-6 - PubMed
51. Clin Neuropharmacol. 1991 Apr;14(2):165-9 - PubMed
52. Adv Neurol. 1987;45:519-23 - PubMed
53. J Neurol Neurosurg Psychiatry. 1988 Apr;51(4):529-33 - PubMed
54. Mayo Clin Proc. 1988 Oct;63(10):969-78 - PubMed
55. Neurology. 1995 Mar;45(3 Suppl 3):S6-12 - PubMed
56. N Y State J Med. 1988 Aug;88(8):420-2 - PubMed
57. Mov Disord. 1995 Sep;10(5):668-71 - PubMed
58. Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):423-7 - PubMed
59. Clin Pharmacol Ther. 1982 Jul;32(1):70-5 - PubMed

Publication Types

• Journal Article